Our findings propose that microRNA-4716–3p may contribute to the development of blood cancer by targeting and controlling the expression of the AKT2 gene, a process that may be modulated by the rs2304186 polymorphism. This evidence concerns the gene AKT2 and hematopoietic and lymphoid system neoplasm.